Biogen Idec is a global biotechnology company focused on discovering, developing, manufacturing and marketing therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia. Co.'s products include: AVONEX (interferon beta-1a), indicated for MS; TYSABRI (natalizumab), indicated for MS and Crohn's disease; FAMPYRA (prolonged-release fampridine tablets), indicated for MS (walking ability); FUMADERM (fumaric acid esters), indicated for psoriasis; and RITUXAN (rituximab), indicated for Non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, and ANCA-associated vasculitis.
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.
